The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer

Nathaniel Deboever; Michael Eisenberg; Alexis Chidi; Boris Sepesi

doi:10.1002/jso.27166

The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer

Nathaniel Deboever, Michael Eisenberg, Alexis Chidi, Boris Sepesi

Thoracic & Cardiovascular Surgery

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.

Original language	English (US)
Pages (from-to)	275-281
Number of pages	7
Journal	Journal of surgical oncology
Volume	127
Issue number	2
DOIs	https://doi.org/10.1002/jso.27166
State	Published - Feb 2023

Keywords

immunotherapy
resectable nonsmall cell lung cancer
targeted therapy

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.27166

Cite this

@article{e46c6f90edf141e3b6dfcdbd7f40abb2,

title = "The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer",

abstract = "As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.",

keywords = "immunotherapy, resectable nonsmall cell lung cancer, targeted therapy",

author = "Nathaniel Deboever and Michael Eisenberg and Alexis Chidi and Boris Sepesi",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2023",

month = feb,

doi = "10.1002/jso.27166",

language = "English (US)",

volume = "127",

pages = "275--281",

journal = "Journal of surgical oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer

AU - Deboever, Nathaniel

AU - Eisenberg, Michael

AU - Chidi, Alexis

AU - Sepesi, Boris

PY - 2023/2

Y1 - 2023/2

N2 - As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.

AB - As the immunotherapeutic milieu in resectable nonsmall cell lung cancer continues to evolve, the field of thoracic oncology actively moves towards better patient selection based on biomarkers and oncogenic drivers. In this article, we review the current standard of oncologic care in this population and discuss the ongoing phase III clinical trials investigating the use of immunotherapy or targeted therapy in the perioperative period. We also discuss genotyping initiatives, biomarkers, and trial endpoints.

KW - immunotherapy

KW - resectable nonsmall cell lung cancer

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85146135492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146135492&partnerID=8YFLogxK

U2 - 10.1002/jso.27166

DO - 10.1002/jso.27166

M3 - Review article

C2 - 36630093

AN - SCOPUS:85146135492

SN - 0022-4790

VL - 127

SP - 275

EP - 281

JO - Journal of surgical oncology

JF - Journal of surgical oncology

IS - 2

ER -

The role of immunotherapy and targeted therapy in the multimodal therapy for resectable lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this